Processing ends
Uranium production ceased in January; restoration obligations became central to the financial statements.
Energy Resources of Australia’s FY2021-FY2025 calendar-year review tracks the end of Ranger uranium processing and the transition to rehabilitation. The central questions are restoration costs, funding and access to designated security—not mining output growth.
Reading the figures: Units are stated above each table or beside the metric. Brackets denote negative amounts. Supported nil is shown as zero; unlike reporting bases remain separately labelled.
Excludes term deposits and trust security.
Separately classified assets.
FY2025 cash expenditure.
Negative equity, not bank debt.
Ranger processing ceased in January 2021 and the final uranium sales were completed in 2022. Subsequent revenue therefore has a different economic meaning: FY2025 revenue is overwhelmingly interest income.
Reported losses are heavily affected by revised rehabilitation estimates and discount unwinding. A smaller statutory loss can coincide with substantial cash rehabilitation spending.
Uranium production ceased in January; restoration obligations became central to the financial statements.
Ranger sales ended while rehabilitation cash payments continued.
The rehabilitation estimate rose sharply; a May entitlement offer raised approximately A$369m before costs.
The entitlement offer secured approximately A$766m before costs, while the Jabiluka property was fully impaired.
Slower tailings dry-out constrained Pit 3 capping, which was suspended in December for the rest of the wet season.
The FY2023 estimate revision drives the largest loss in this period. FY2025 instead includes a A$32.240m estimate credit, but A$131.291m discount unwinding remains an expense. These adjustments should not be confused with the annual rehabilitation payment.
A$ million
AI-generated presentation · values from Results during the transition to rehabilitation; no missing values plotted as zero.
A$ million
AI-generated presentation · values from Results during the transition to rehabilitation; no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue from continuing operations | 201.007 | 55.309 | 34.182 | 37.196 | 58.871 |
| Net loss after tax | (650.212) | (160.553) | (1,388.094) | (245.975) | (50.320) |
| Rehabilitation estimate change: income / (expense) | (668.149) | (62.157) | (1,349.272) | (69.096) | 32.240 |
Calendar years ended 31 December; extracted A$ thousands converted to A$ million.
All Ranger uranium sales were completed in 2022. Later revenue is principally interest and other income, not a resumption of uranium sales.
Positive FY2025 estimate change is a credit to income; it is not a cash receipt.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2024 | FY2025 |
|---|---|---|
| Total rehabilitation provision | 2,422.792 | 2,300.818 |
Calculated from rehabilitation-specific note balances. Broader balance-sheet provisions also contain other obligations and are not substituted.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
The cash balance fell in FY2025 while term deposits increased. The broader A$1,158.981m financial-asset figure also includes government security receivable, so presenting it all as freely available cash would be misleading.
A$ million
AI-generated presentation · values from Cash spending and funding; no missing values plotted as zero.
A$ million
AI-generated presentation · values from Cash spending and funding; no missing values plotted as zero.
A$ million
AI-generated presentation · values from Cash versus designated rehabilitation security; no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Rehabilitation cash payments | (153.149) | (194.190) | (210.615) | (176.229) | (221.025) |
| Net operating cash flow | (37.934) | (146.963) | (223.246) | (183.948) | (192.215) |
| Net investing cash flow | (0.043) | 59.276 | 1.268 | (459.686) | (79.868) |
| Net financing cash flow | (2.512) | 10.944 | 351.811 | 758.000 | (0.863) |
Rehabilitation payments are included in operating cash flow, not additional to it.
FY2024-FY2025 investing outflows principally include placement of funds into term deposits; this is not the same as mine construction or money consumed.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash and equivalents only | 163.872 | 87.116 | 216.951 | 331.332 | 58.374 |
| Total assets | 855.930 | 679.771 | 828.800 | 1,345.081 | 1,173.901 |
| Equity / (net deficit) | (442.422) | (603.657) | (1,627.300) | (1,114.619) | (1,165.270) |
Cash alone excludes term deposits and government security receivables shown below. Negative equity is not the same as outstanding bank borrowings.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2024 | FY2025 |
|---|---|---|
| Cash and equivalents | 331.332 | 58.374 |
| Term deposits | 460.000 | 540.000 |
| Government security receivable / Trust Fund | 535.107 | 560.607 |
| Sum of these three asset categories | 1,326.439 | 1,158.981 |
The combined figure is not all unrestricted cash. The government security receivable relates to the rehabilitation trust, and bank guarantees are not cash assets.
Do not add these amounts to total assets: they are already included there.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Management expected the 2024 raising to support work to around Q3 2027 and identified a need for further funding beyond it. The December 2025 rehabilitation authority, effective January 2026, supports continued restoration and monitoring rather than renewed uranium processing.
The report retains the directors’ conclusion that no material going-concern uncertainty arose from their assessed range of outcomes, alongside the substantial future funding requirement. Going concern was a key audit matter; that is not a modified audit opinion.
The compulsory-acquisition process and Jabiluka court matters described in the annual extraction are not treated as finally resolved here. Subsequent hearing dates remain separate from the December balance sheet.
Prepared solely from the existing year-by-year extraction datasets. No raw annual-report body, PDF, new database lookup or financial web research was used. Review is against those stored extractions, not a new independent original-document audit.
The source references in this report identify the public disclosures used and should be read with the associated section, table and reporting-period qualifications. This report paraphrases, organises and compares those disclosures for descriptive and educational purposes rather than reproducing source text.
Copyright and other rights in linked reports, company names, logos and third-party materials remain with their respective owners. MII Research does not claim affiliation with or endorsement by the company covered in this report, the ASX or cited organisations.
This report uses AI actively and extensively for evidence extraction, comparison, organisation, calculation checks, drafting, translation planning and presentation. Material claims received reasonable editorial review against cited public sources; this was not an audit, assurance engagement or independent verification. Limitations in public sources, AI systems and review may leave errors, omissions, inconsistencies or translation, classification and interpretation errors.
Any AI-generated visual accompanying this report must carry an adjacent, visible AI-generated label or caption. Such visuals are illustrative rather than source evidence and do not replace the cited annual-report text, table or section source.
This record is for general descriptive and educational information only. It is not financial-product, investment, legal, tax, technical or other professional advice; it is not a securities recommendation, valuation, target price, offer, solicitation or invitation to buy, sell or hold.
It does not consider any reader’s objectives, financial situation, needs, knowledge, experience or risk tolerance. Independently verify material information against the primary disclosures, obtain appropriate independent professional advice and do not use this record as the sole or primary basis for any decision.
Public sources are used in good faith, but no representation or warranty is made as to accuracy, completeness, reliability, currency or fitness for a particular purpose. To the maximum extent permitted by law, MII Research disclaims liability for direct, indirect, incidental, consequential, opportunity or investment loss arising from use of or reliance on this record; nothing excludes or limits liability that cannot lawfully be excluded or limited.
Report suspected errors to MII Research with the relevant report section and primary-source document and page reference so that the record can be reviewed and corrected where appropriate.